Can Exosomes Help With Wound Healing & Scarring? What the Research Says

When skin is injured, healing involves much more than simply closing a wound.

Cells have to communicate. Inflammation has to be controlled. New blood vessels may need to form. Fibroblasts produce and reorganize extracellular matrix. New skin grows across the wound, and collagen continues remodeling long after the surface appears healed.

When this process becomes disrupted, wounds can heal slowly or leave excessive or disorganized scar tissue behind.

That complex biology is one reason extracellular vesicles—including exosomes—have become an increasingly active area of wound-healing research.

Scientists are investigating whether the molecular signals carried by extracellular vesicles can influence several stages of tissue repair, including inflammation, angiogenesis, re-epithelialization, fibroblast activity, collagen organization and later scar remodeling.

The evidence has grown substantially.

A 2025 systematic review and meta-analysis identified 83 preclinical studies examining mesenchymal-stem-cell-derived extracellular vesicles in wound healing and skin regeneration. Researchers reported favorable findings involving wound closure, blood-vessel formation, collagen deposition and scar-related outcomes, while also identifying substantial differences in EV production and experimental protocols between studies.

More importantly, the field is beginning to move into people.

A 2026 randomized controlled study involving 75 patients with postoperative facial scars reported greater short-term improvements in several scar measurements when exosome-based formulations were combined with fractional laser treatment compared with laser treatment alone.

So what exactly is the research finding?

What Does the Research Show?

Extracellular-vesicle research surrounding wound healing spans several levels of evidence.

Laboratory studies have investigated how EVs interact with fibroblasts, keratinocytes, endothelial cells and signaling pathways involved in tissue repair.

Animal studies have investigated wound closure, angiogenesis, collagen deposition, inflammation, re-epithelialization and scar formation.

And early human studies are now examining EV-based preparations in wounds and scars.

A 2025 meta-analysis of MSC-derived EVs analyzed preclinical wound-healing research and found that the field had expanded enough for investigators to quantitatively evaluate outcomes including wound closure, scar width, blood-vessel density and collagen deposition.

Another 2025 systematic review and meta-analysis examining mammalian-derived exosomes included 19 studies and reported favorable findings involving angiogenesis, re-epithelialization and collagen deposition, along with reduced scar formation. The authors also emphasized substantial variability in cellular sources, biomaterials and delivery methods.

This growing body of evidence helps explain why EVs are being investigated across both regenerative wound research and scar remodeling.

Why Are Exosomes Being Studied for Wound Healing?

Wound healing is usually described in overlapping biological phases.

Immediately after an injury, the body works to stop bleeding and initiate an inflammatory response.

Cells then migrate into the damaged area. New extracellular matrix is produced. Blood vessels develop. Keratinocytes move across the wound surface to restore the skin barrier.

Later, collagen and other structural components undergo prolonged remodeling.

Successful healing requires coordination between these processes.

Extracellular vesicles are interesting to researchers because they are one way cells communicate with one another. For background on the particles themselves, see where exosomes come from.

EVs can transport biological cargo that includes proteins, lipids and nucleic acids. Rather than behaving like inert particles, they can participate in signaling between cells.

Research reviews have repeatedly identified several areas of wound biology potentially influenced by MSC-derived EVs, including fibroblast and keratinocyte activity, endothelial-cell behavior, inflammatory signaling, macrophage polarization, angiogenesis and extracellular-matrix remodeling.

That means the research question isn't simply:

“Can exosomes close a wound?”

A more accurate question is:

That's the question much of the current research is trying to answer.

What Are Researchers Finding About Wound Closure?

One of the most commonly measured outcomes in preclinical research is the percentage of a wound that closes over time.

The 2025 systematic review and meta-analysis by Zhu and colleagues included 83 studies of MSC-derived small extracellular vesicles and apoptotic extracellular vesicles.

Researchers performed meta-analyses of wound-closure rate, scar width, blood-vessel density and collagen deposition.

Their analysis found substantial evidence of biological activity across diabetic and non-diabetic animal wound models.

The researchers also found something particularly important for understanding exosome research:

Results varied depending on the EV preparation and how it was used.

Different EV subtypes produced different patterns of findings.

Different MSC sources also appeared to perform differently depending on the outcome being measured.

For example, adipose-derived MSC preparations showed particularly favorable findings for wound closure and collagen deposition in the authors' subgroup analyses, while bone-marrow-derived MSC preparations performed better in revascularization analyses.

That doesn't establish that one source is universally better.

It demonstrates something we've seen repeatedly across the EV literature:

What About Diabetic Wounds?

Chronic diabetic wounds have received particular attention because their normal healing processes can become disrupted.

A 2024 systematic review and meta-analysis focused specifically on extracellular vesicles derived from adipose-derived mesenchymal stromal/stem cells in preclinical diabetic-wound models.

Researchers identified 20 full-text studies for qualitative analysis and included 12 in quantitative meta-analysis.

Compared with controls, the pooled analysis reported favorable effects on:

• wound closure
• neovascularization
• collagen deposition

The authors nevertheless noted that risk of bias was unclear across the included studies.

Another 2025 wound-healing meta-analysis likewise reported favorable findings while emphasizing that reliance on rodent models remains a significant limitation to clinical translation.

So these experiments are valuable for understanding the biology, but animal wound healing should not be presented as established human clinical efficacy.

What Are Researchers Finding About Scarring?

Closing a wound is only part of healing.

What happens afterward matters too.

Collagen deposited during repair continues to reorganize as the tissue matures. Excessive or poorly organized remodeling can contribute to visible scar formation.

That's why researchers aren't studying EVs only for faster wound closure.

They're also investigating whether EV-mediated signaling may influence how repaired tissue remodels.

Preclinical research has reported findings involving scar width, collagen organization and fibrotic remodeling. The 2025 Zhu meta-analysis specifically included scar width among its quantitative outcomes.

A 2026 clinical and translational review of exosomes in cutaneous wound healing similarly described findings across animal models involving wound closure, neovascularization, collagen architecture and later fibrotic remodeling.

And unlike much of the broader wound-healing literature, scar research now includes randomized human data.

Research Highlight: Postoperative Facial Scars in 75 Patients

Park & Park, 2026 — Life

A 2026 randomized controlled clinical study examined exosome-based formulations in 75 people with postoperative facial scars.

Participants were randomly assigned 1:1:1 to one of three groups:

• fractional non-ablative Nd:YAG laser alone
• laser plus a human-derived exosome formulation
• laser plus a plant-derived exosome formulation

Participants completed five treatment sessions at two-week intervals.

Researchers evaluated the scars using several methods, including the modified Vancouver Scar Scale, Patient and Observer Scar Assessment Scale, and objective imaging.

What did researchers report?

The modified Vancouver Scar Scale improved by:

• 0.7 points in the laser-only group
• 2.5 points in the laser + human-derived exosome group
• 2.8 points in the laser + plant-derived formulation group

The difference among the three groups was statistically significant (p = 0.03).

Observer-reported POSAS scores also showed significantly different improvements between groups — 3.1, 5.4 and 5.3 points respectively (p = 0.03). Patient-reported POSAS improvements were similar across the three groups and were not statistically significantly different (p = 0.26).

Objective grayscale imaging showed changes of:

• 2.9 in the laser-only group
• 11.3 in the human-derived exosome group
• 13.1 in the plant-derived group

Again, the between-group difference was statistically significant (p = 0.01).

Researchers also reported differences involving redness, pigmentation, pores and wrinkle measurements.

No serious adverse events were reported during the study.

What is the important limitation?

This was combination treatment.

There's another reason to interpret this study carefully: the human- and plant-derived formulations produced comparable responses across the measured outcomes, and the authors themselves caution against interpreting the findings as definitive efficacy or superiority.

Still, this study is important because it moves scar-related EV research beyond cell cultures and animal models into a randomized human clinical setting.

What About the Larger Preclinical Evidence?

Individual studies become more useful when they're considered alongside the broader literature.

Zhu and colleagues' 2025 systematic review identified 83 preclinical studies examining MSC-derived EVs in wound healing and skin regeneration.

The investigators found enough comparable research to perform quantitative analyses of four important outcomes:

• wound closure
• scar width
• blood-vessel density
• collagen deposition

But the review also exposed how heterogeneous the field remains.

Studies differed in:

• cell source
• EV collection conditions
• isolation methods
• storage
• modification
• dose
• administration route
• treatment frequency

The authors specifically identified this variability as a major issue requiring standardization before clinical translation.

That's an important finding in itself.

A paper can report encouraging results while still leaving open the question of whether another EV preparation would behave the same way. For how preparations are described and verified, see extracellular vesicle characterization and testing.

Why Angiogenesis Matters

Healing tissue needs oxygen and nutrients.

Angiogenesis—the development of new blood vessels—is therefore an important part of tissue repair and one of the recurring areas investigated in EV research.

Laboratory and animal studies have reported effects involving endothelial-cell activity and signaling pathways associated with new blood-vessel development.

The 2025 meta-analysis by Zhu and colleagues evaluated blood-vessel density directly and found that different types and sources of EV preparations produced different patterns of results.

Again, this suggests that researchers shouldn't treat every extracellular-vesicle preparation as biologically interchangeable.

Why Collagen Is More Complicated Than “More Is Better”

Collagen is essential to wound repair.

But simply producing more collagen isn't necessarily the goal.

The timing, organization and remodeling of collagen all matter.

During early wound repair, collagen helps provide structural support. Later, that matrix is reorganized as the tissue matures.

Researchers are therefore studying EVs not only for effects on collagen production but also for their potential influence on extracellular-matrix remodeling and scar architecture.

Recent systematic reviews have reported findings involving collagen deposition and scar-related outcomes, while emphasizing that different preparations and experimental conditions can produce different effects. Those same variables — source, manufacturing and characterization — are what how to evaluate an exosome product walks through.

That distinction is important when interpreting headlines about exosomes and “collagen production.”

The biology is more complicated than simply maximizing collagen.

The Evidence Is Beginning to Move Into Humans

The overall EV clinical literature remains small compared with the enormous preclinical literature.

But wound healing is actually one of the more represented areas of early human EV research.

A systematic review of published clinical studies using cell-derived extracellular vesicles identified 25 clinical trials through September 2024.

Wound healing represented the second-largest disease category, accounting for five of the 25 trials.

Mesenchymal stromal cells were the most common EV source across the overall clinical literature.

That doesn't mean clinical efficacy has been established.

It means the field has progressed far enough that wound healing is no longer exclusively a laboratory or animal-research question.

The 75-person postoperative-scar study published in 2026 provides another example of that progression.

Why EV Source and Preparation Matter

This may be one of the most important lessons from the wound-healing literature.

“Exosomes” is not a complete description of a biological preparation.

Across published research, investigators have used extracellular vesicles originating from different cell and biological sources.

They have also used different:

• culture conditions
• isolation techniques
• purification methods
• characterization methods
• particle concentrations
• formulations
• biomaterials
• delivery methods
• treatment schedules

The 2025 Zhu meta-analysis specifically found substantial heterogeneity in collection conditions, separation methods, storage, modification, treatment dose, administration route and treatment frequency.

The 2025 diabetic-wound meta-analysis likewise emphasized variability in cell sources, biomaterials and delivery methods.

That means a positive result from one preparation cannot automatically be transferred to another product simply because both are described as containing extracellular vesicles or exosomes.

Why Results May Vary

As with many biologically active interventions, people may not respond identically. Individual genetics, age, underlying biology, disease severity and other person-specific factors may influence biological responses. The extracellular-vesicle preparation itself—including its source, manufacturing, characterization and formulation—may also matter. Researchers are still working to understand which factors may help predict how individuals respond.

For wound healing specifically, there are additional variables.

A fresh surgical wound isn't biologically identical to a chronic diabetic ulcer.

A postoperative facial scar isn't the same as an open wound.

And a topical EV formulation delivered after fractional laser treatment isn't equivalent to an EV preparation delivered using another route or biomaterial.

These differences are why individual studies need to be interpreted in the context of what was actually studied.

The Bottom Line

Wound healing has become one of the more extensively studied areas of extracellular-vesicle research.

Preclinical evidence now spans dozens of studies investigating wound closure, angiogenesis, re-epithelialization, inflammation, collagen deposition and scar remodeling. One 2025 systematic review alone identified 83 qualifying preclinical studies.

The evidence is also beginning to move into humans.

A 2026 randomized study involving 75 postoperative facial-scar patients reported greater short-term improvements in several scar measurements when exosome-based formulations were combined with fractional laser therapy compared with laser treatment alone.

At the same time, the literature makes another point equally clear:

The source, manufacturing, isolation, characterization, formulation and delivery of extracellular vesicles vary considerably between studies. Researchers are also investigating extracellular vesicles in adjacent areas of skin biology — see what the research says about exosomes and skin rejuvenation.

The field still needs larger controlled human studies and better standardization to determine which findings translate reliably from experimental models into people.